Organon Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Organon OGN reported $1.61 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 0.1%. EPS of $1.12 for the same period compares to $1.31 a year ago.

The reported revenue represents a surprise of -1.13% over the Zacks Consensus Estimate of $1.63 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +5.66%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Women's Health- U.S.- Nexplanon/Implanon NXT

  : $171 million compared to the $155.74 million average estimate based on three analysts. The reported number represents a change of +7.6% year over year.

• Geographic Revenue- U.S.

  $388 million compared to the $409.79 million average estimate based on three analysts. The reported number represents a change of +4.6% year over year.

• Revenue- Women's Health- U.S.- NuvaRing

  : $10 million versus $16.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -41.2% change.

• Revenue- Women's Health- U.S.- Follistim AQ

  : $22 million versus $27.70 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -15.4% change.

• Revenue- Women's Health- Nexplanon/Implanon NXT

  : $242 million compared to the $218.97 million average estimate based on three analysts. The reported number represents a change of +13.1% year over year.

• Revenue- Biosimilars Total

  : $164 million versus the three-analyst average estimate of $176.39 million. The reported number represents a year-over-year change of +21.5%.

• Revenue- Women's Health- NuvaRing

  : $29 million versus $37.37 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -27.5% change.

• Revenue- Women's Health- Follistim AQ

  : $62 million versus $64.88 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.4% change.

• Revenue- Women?s Health Total

  : $449 million compared to the $441.33 million average estimate based on three analysts. The reported number represents a change of +2.5% year over year.

• Revenue- Established Brands- Non-Opioid Pain, Bone and Dermatology- Other

  : $78 million versus $78.06 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.9% change.

• Revenue- Established Brands- Non-Opioid Pain, Bone and Dermatology- Diprospan

  : $37 million versus $23.96 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +208.3% change.

• Revenue- Established Brands- Non-Opioid Pain, Bone and Dermatology- Fosamax

  : $35 million compared to the $43.76 million average estimate based on three analysts. The reported number represents a change of -20.5% year over year.

Shares of Organon have returned +0.3% over the past month versus the Zacks S&P 500 composite's -6.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

To read this article on Zacks.com click here.